Objective: We compared patients with neovascular age-related macular degeneration (nvAMD), diabetic macular oedema (DMO) and other macular pathologies testing their vision with the hyperacuity home-monitoring app Alleye to patients not performing home-monitoring regarding clinical outcomes and clinical management.
Design: Matched-pair analysis.
Setting: Retina Referral Centre, Switzerland.
Participants: For each eye using Alleye, we matched 2-4 controls not using home-monitoring based on age, gender, number of previous intravitreal injections (IVI), best corrected visual acuity (BCVA) (Early Treatment Diabetic Retinopathy Study letters), central macular thickness (CRT) and time point of enrolment, using the Mahalanobis distance matching algorithm. We included 514 eyes (288 patients); 107 eyes with nvAMD using home monitoring and 218 controls not using home monitoring, 25 eyes with DMO (n=52 controls) and 40 eyes with miscellaneous conditions (n=72 controls). 173 eyes (33.7%) received no IVI during follow-up.
Main Outcome Measures: Improvement of ≥5 letters, number of injection visits and treatment retention after correcting for differences in baseline characteristics with multivariate analyses.
Results: The mean follow-up duration was 809 days (range 147-1353) and the mean number of IVI/year among treated eyes was 6.7 (SD 3.1). Mean age at baseline was 70.4 years (SD 10.9), BCVA was 77.6 letters (SD 11.6) and CRT was 263.6 µm (SD 86.7) and was similar between patients using and not using home monitoring. In multivariate analyses, patients using home monitoring had a higher chance to improve visual acuity by ≥5 letters (OR 1.67 (95% CI 1.01 to 2.76; p=0.044)) than controls. Treated eyes using home monitoring had less injection visits/year (-0.99 (95% CI -1.59 to -0.40; p=0.001)) and a longer treatment retention +69.2 days (95% CI 2.4 to 136.0; p=0.042). These effects were similar across retinal pathologies.
Conclusions: This data suggest that patients capable of performing mobile hyperacuity home monitoring benefit in terms of visual acuity and discontinue treatment less often than patients not using home monitoring.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9066342 | PMC |
http://dx.doi.org/10.1136/bmjopen-2021-056940 | DOI Listing |
Int J Retina Vitreous
January 2025
Department of Retina and Vitreous, Narayana Nethralaya, #121/C, 1st R Block, Chord Road, Rajaji Nagar, Bengaluru, 560010, India.
Purpose: To evaluate the predictive accuracy of various machine learning (ML) statistical models in forecasting postoperative visual acuity (VA) outcomes following macular hole (MH) surgery using preoperative optical coherence tomography (OCT) parameters.
Methods: This retrospective study included 158 eyes (151 patients) with full-thickness MHs treated between 2017 and 2023 by the same surgeon and using the same intraoperative surgical technique. Data from electronic medical records and OCT scans were extracted, with OCT-derived qualitative and quantitative MH characteristics recorded.
BMC Ophthalmol
January 2025
Shaanxi Eye Hospital, Xi'an People's Hospital (Xi'an Fourth Hospital), Affiliated People's Hospital of Northwest University, Xi'an, 710004, China.
Background: This study aimed to identify the clinical characteristics of cases that is related to the response rate of adalimumab (ADA) treatment.
Methods: A retrospective review of medical records was conducted for pediatric patients with non-infectious uveitis undergoing ADA treatment for a minimum of six months. The patients were stratified into two groups: those with anterior segment inflammation (ASI+) and those without anterior segment inflammation (ASI-).
BMC Ophthalmol
January 2025
Department of Ophthalmology, Guizhou Provincial People's Hospital, No.83, Zhongshan Road, Nanming District, Guiyang, Guizhou Province, 550002, China.
Objective: We aimed to investigate the occurrence and factors influencing early visual acuity (VA) outcomes and reoperation rates in patients with open globe injuries (OGI) and develop a nomogram for predicting early visual acuity outcomes and reoperation rate.
Methods: We conducted a retrospective review of data from 121 patients with treated OGI. Relevant information of all patients with OGI were collected after a 1-month timeframe post-surgery.
Eye (Lond)
January 2025
Department of Translational Medicine, University of Ferrara, Ferrara, Italy.
Objectives: The aim of the study was to evaluate anatomical and functional outcomes of the Smaller-Incision New Generation Implantable Miniature Telescope (SING IMT™) in patients with bilateral advanced age-related macular degeneration (AMD).
Methods: This non-comparative retrospective single-surgeon interventional case series included patients with bilateral late-stage AMD who underwent cataract surgery and SING IMT™ implantation at the Sant'Anna University Hospital, University of Ferrara, Italy. The main outcome measures included corrected distance (CDVA) and near visual acuity (CNVA), endothelial cell loss (ECL), and incidence of complications.
Mol Cell Probes
January 2025
Institute of Molecular and Clinical Ophthalmology Basel, Basel, Switzerland, Mittlere Strasse 91, CH-4031. Electronic address:
The rapid advancements in the field of genetics have significantly propelled the development of gene therapies, paving the way for innovative treatments of various hereditary disorders. This review focuses on the genetics of ophthalmologic conditions, highlighting the currently approved ophthalmic gene therapy and exploring emerging therapeutic strategies under development. Inherited retinal dystrophies represent a heterogeneous group of genetic disorders that manifest across a broad spectrum from infancy to late middle age.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!